Published in Clin Exp Rheumatol on November 08, 2005
An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord (2007) 3.71
Research priorities for non-pharmacological therapies for common musculoskeletal problems: nationally and internationally agreed recommendations. BMC Musculoskelet Disord (2009) 1.38
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Outcomes in registered, ongoing randomized controlled trials of patient education. PLoS One (2012) 0.84
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford) (2014) 0.80
Patient-important outcomes in randomized controlled trials in critically ill patients: a systematic review. Ann Intensive Care (2017) 0.75
The degree of cartilage degradation assessed by serum biomarker levels changes after arthroscopic knee synovectomy in rheumatoid arthritis patients. Int Orthop (2017) 0.75
Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series. Rheumatol Int (2013) 0.75
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum (1990) 27.50
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials (1995) 9.85
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns (1998) 5.40
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
A critical appraisal of the efficacy of continuing medical education. JAMA (1984) 4.95
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA (1998) 4.73
Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA (1994) 4.49
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess (1999) 4.45
Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol (1993) 4.39
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet (2000) 4.16
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
The Epidemiology of low back pain. Best Pract Res Clin Rheumatol (2010) 3.96
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
Rapid bacteriological diagnosis of pyogenic meningitis by latex agglutination. Lancet (1974) 3.64
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care (1996) 3.37
n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ (1994) 3.34
The Ottawa patient decision aids. Eff Clin Pract (1999) 3.22
Raised ESR in polymyalgia rheumatica no longer a sine qua non? Lancet (1996) 3.20
Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making (1998) 3.18
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am (1993) 2.85
Repetitive strain injury. BMJ (1993) 2.81
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
Pneumococcal antigen in lobar pneumonia. J Clin Pathol (1975) 2.75
Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev (2002) 2.65
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol (1990) 2.50
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
The International Clinical Epidemiology Network (INCLEN): a progress report. J Clin Epidemiol (1991) 2.32
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Setting educational priorities for learning the concepts of population health. Med Educ (1989) 2.19
Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis (2008) 2.19
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage (2002) 2.14
Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol (1983) 2.13
Sleep and ventricular premature beats. Circulation (1973) 2.10
The use of botulinum toxin in the management of burns itching: preliminary results. Burns (2012) 2.04
Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) 2.01
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
A comparison of resident performance on real and simulated patients. J Med Educ (1982) 1.92
Knowledge and clinical problem-solving. Med Educ (1985) 1.91
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage (2002) 1.89
School feeding for improving the physical and psychosocial health of disadvantaged elementary school children. Cochrane Database Syst Rev (2007) 1.88
Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci (1993) 1.87
Hydroxymethyluracil DNA glycosylase in mammalian cells. Proc Natl Acad Sci U S A (1984) 1.83
Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol (1999) 1.72
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69
Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med (2000) 1.68
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum (2001) 1.68
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol (1983) 1.66
Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis (1980) 1.64
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol (2001) 1.64
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) (2000) 1.64
Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.63
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum (2000) 1.62
Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum (1997) 1.61
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
RSI--regional pain syndrome: the importance of nomenclature. Br J Rheumatol (1989) 1.58
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum (1999) 1.57
Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med (1993) 1.57
Acute calcific tendinitis of the rectus femoris. J Bone Joint Surg Br (1996) 1.56
T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum (1998) 1.55
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis (2007) 1.55
Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum (2000) 1.55
An hypothesis paper on practice environment and the provision of health care: could hospital occupancy rates effect quality? J Qual Clin Pract (2001) 1.50
Fibrin degradation products in the serum and cerebrospinal fluid of patients with group A meningococcal meningitis. J Clin Pathol (1974) 1.47
Guidelines for the clinical and economic evaluation of health care technologies. Soc Sci Med (1986) 1.47
A methodological perspective on process measures of the quality of medical care. Clin Invest Med (1979) 1.47
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 1.46
Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res (1987) 1.42
Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev (2001) 1.42
Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics (1996) 1.41
The rich-poor gap in global health research: challenges for Canada. CMAJ (2001) 1.40